Ipamorelin research has produced one of the cleanest and most active bodies of preclinical literature on selective growth hormone secretagogues. As the ghrelin receptor agonist component of the CJC-1295/Ipamorelin combination, Ipamorelin brings a well characterized selectivity profile and a substantial body of pituitary research to the formulation. This article reviews the published literature on Ipamorelin, with a focus on its selective binding at the growth hormone secretagogue receptor (GHS-R1a), its growth hormone releasing activity in research models, and how its profile distinguishes it from earlier peptides in the GHRP class.
Ipamorelin Research: Selective GHRP and Ghrelin Receptor Binding Studies
CJC-1295 / Ipamorelin · Published April 8, 2026 · Updated May 18, 2026 · 8 min read
Quick Answer
Ipamorelin is a selective pentapeptide ghrelin receptor agonist studied in research for clean growth hormone release without significant cortisol or prolactin effects. Studies examine GHS-R1a binding, somatotroph activation, and combined activity with GHRH analogs across rodent pituitary models. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
Frequently Asked Questions
What is Ipamorelin in research contexts?
+
Ipamorelin is a synthetic pentapeptide and selective ghrelin receptor (GHS-R1a) agonist. It is studied in research models as a growth hormone secretagogue with minimal effects on cortisol or prolactin secretion.
How does Ipamorelin compare to other GHRPs in research?
+
Compared to GHRP-2 and GHRP-6, Ipamorelin produces equivalent or stronger GH release with markedly reduced cortisol, ACTH, and prolactin elevation, making it the preferred research tool when selective ghrelin receptor activation is desired.
What downstream signaling does GHS-R1a activation trigger?
+
Ghrelin receptor activation couples to Gq, activating phospholipase C, generating IP3 and DAG, releasing intracellular calcium, and activating PKC. This calcium signaling drives somatotroph exocytosis of stored GH granules.
Is Ipamorelin approved for human use?
+
No. Ipamorelin is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.
Glossary
Key terms used in this article.
- GHS-R1a
- Growth hormone secretagogue receptor 1a, the ghrelin receptor through which ipamorelin signals.
- GHRP
- Growth hormone-releasing peptide, a class of synthetic ghrelin receptor agonists that stimulate GH release.
- Ghrelin
- The endogenous 28-amino-acid acylated peptide hormone that activates GHS-R1a and stimulates appetite and GH release.
- Selectivity
- The pharmacological preference of a ligand for one receptor or pathway over others, minimizing off-target effects.
- Phospholipase C (PLC)
- An enzyme that cleaves PIP2 into IP3 and DAG, driving calcium release and PKC activation downstream of Gq signaling.
- IP3
- Inositol trisphosphate, a second messenger that triggers calcium release from the endoplasmic reticulum.
More from the Blog
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
